Dergiler / Turkish Journal of Internal Medicine / 2021 / Cilt: 3 - Sayı: 3

A possible contributor to erythropoiesis-stimulating agents requirement in hemodialysis: Paraoxonase 1 activity

Sayfa
116–122
Yayın Tarihi
2021-07-29
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

The mean PON1 activity of the ESA+ group was significantly lower than the ESA– group (191.4 ±118.8 and 488.1±174.9,respectively; p

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Background: Anemia is one of the most prevalent complications of chronic kidney disease (CKD).
📊
Temel Bulgular & Veri:In CKD-related anemia, circulating erythrocytes have a decreased life span.
💡
Sonuç & Katkı:The mean PON1 activity of the ESA+ group was significantly lower than the ESA– group (191.4 ±118.8 and 488.1±174.9,respectively; p
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Paraoxanase 1 · erythropoiesis-stimulating agents · hemodialysis

Abstract

Background: Anemia is one of the most prevalent complications of chronic kidney disease (CKD). In CKD-related anemia, circulating erythrocytes have a decreased life span. Paraoxonase-1 (PON1) activity is one of the essential factors protecting cell membranes, e.g., erythrocytes, from lipid peroxidation under normal conditions. In this study, we investigated PON1 activity in hemodialysis (HD) patients with and without erythropoiesis-stimulating agents (ESA) therapy and the possible relationship of PON1 activity levels with the ESA dose required. Methods: This study is composed of patients undergoing HD with a minimum dialysis vintage of six months. We excluded cases with an active infection, cardiovascular events and malignancy, hypo- or hyperthyroidism, central venous catheters, iron deficiency, cystic kidney diseases, nephrectomy, and routine C-reactive protein (CRP) levels higher than reference range within the last six months. Results: Baseline characteristics, laboratory parameters, oxidative stress, and systemic inflammatory indices were similar between groups. The mean PON1 activity of the ESA+ group was significantly lower than the ESA– group (191.4 ±118.8 and 488.1±174.9,respectively; p

🔖

Bu Makaleye Atıf Yap

KORUCU, B., HACI, H., BALİ, E. B., DERİCİ, M. K., GUZ, G. (2021). A possible contributor to erythropoiesis-stimulating agents requirement in hemodialysis: Paraoxonase 1 activity. Turkish Journal of Internal Medicine, Cilt: 3 - Sayı: 3, 116–122. https://ajindex.com/articles/809038

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (11)

  1. Stauffer ME, Fan T (2014) Prevalence of anemia in chronic kidney disease in the United States. PLoS One 9 Akizawa T, Okumura H, Alexandre AF, Fukushima A, Kiyabu G, Dorey J (2018) Burden of anemia in chronic kidney disease patients in Japan: a literature review. Ther Apher Dial 22:444-56
  2. Zadrazil J, Horak P (2015) Pathophysiology of anemia in chronic kidney diseases: A review. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 159:197-202
  3. Wilmink J, Rosengarten P, Vet R, Goudsmit R (1982) Serum erythropoietin (ESF) titers in anemia of chronic renal failure. The Journal of laboratory and clinical medicine 100:720-34
  4. Ross RP, McCrea JB, Besarab A (1994) Erythropoietin response to blood loss in hemodialysis patients in blunted but preserved. ASAIO journal (American Society for Artificial Internal Organs: 1992) 40:M880-5 Brimble KS, McFarlane A, Winegard N, Crowther M, Churchill DN (2006) Effect of chronic kidney disease on red blood cell rheology. Clin Hemorheol Microcirc 34:411-20
  5. Bissinger R, Artunc F, Qadri SM, Lang F (2016) Reduced erythrocyte survival in uremic patients under hemodialysis or peritoneal dialysis. Kidney Blood Press Res 41:966-77
  6. Glassock RJ (2008) Uremic toxins: what are they? An integrated overview of pathobiology and classification. J Ren Nutr 18:2-6
  7. Korol L (2015) MODELING IN VITRO PATHWAYS OF ACTIVATION OF LIPID PEROXIDATION AND PROTEIN IN CHRONIC KIDNEY DISEASE. Fiziolohichnyi zhurnal (Kiev, Ukraine: 1994) 61:92-97
  8. Rosenblat M, Vaya J, Shih D, Aviram M (2005) Paraoxonase 1 (PON1) enhances HDL-mediated macrophage cholesterol efflux via the ABCA1 transporter in association with increased HDL binding to the cells: a possible role for lysophosphatidylcholine. Atherosclerosis 179:69-77
  9. Huang Y, Wu Z, Riwanto M, Gao S, Levison BS, Gu X, Fu X, Wagner MA, Besler C, Gerstenecker G (2013) Myeloperoxidase, paraoxonase-1, and HDL form a functional ternary complex. The Journal of clinical investigation 123:3815-28
  10. Ferretti G, Bacchetti T, Busni D, Rabini R, Curatola G (2004) Protective effect of paraoxonase activity in high-density lipoproteins against erythrocyte membranes peroxidation: a comparison between healthy subjects and type 1 diabetic patients. The Journal of Clinical Endocrinology & Metabolism 89:2957-62
  11. Motta S, Letellier C, Ropert M, Motta C, Thiébault J (2009) Protecting effect of vitamin E supplementation on submaximal exercise-induced oxidative stress in sedentary dogs as assessed by erythrocyte membrane fluidity and paraoxonase-